Corvus Pharmaceuticals, Inc. financial data

Symbol
CRVS on Nasdaq
Industry
Pharmaceutical Preparations
Location
863 Mitten Road, Suite 102, Burlingame, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 424 % -3.39%
Debt-to-equity 18 % -8.83%
Return On Equity -60 % +8.32%
Return On Assets -50.8 % +6.97%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49 M shares +5.3%
Common Stock, Shares, Outstanding 49 M shares +5.3%
Entity Public Float 84.2 M USD +146%
Common Stock, Value, Issued 5 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 49 M shares +5.33%
Weighted Average Number of Shares Outstanding, Diluted 49 M shares +5.33%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16 M USD -33.2%
General and Administrative Expense 7.08 M USD -8.82%
Operating Income (Loss) -23.1 M USD +27.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -41.3 M USD +4.47%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -24.9 M USD +39.2%
Earnings Per Share, Basic -0.51 USD/shares +42%
Earnings Per Share, Diluted -0.51 USD/shares +42%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.46 M USD -22.8%
Cash, Cash Equivalents, and Short-term Investments 22.1 M USD -35.9%
Accounts Receivable, after Allowance for Credit Loss, Current 26 K USD
Other Assets, Current 267 K USD +104%
Assets, Current 22.9 M USD -35.7%
Property, Plant and Equipment, Net 213 K USD -35.5%
Operating Lease, Right-of-Use Asset 865 K USD -55.7%
Other Assets, Noncurrent 89 K USD -31%
Assets 40.1 M USD -31.1%
Accounts Payable, Current 1.61 M USD +14.4%
Employee-related Liabilities, Current 589 K USD -10.5%
Liabilities, Current 6.72 M USD -18.9%
Operating Lease, Liability, Noncurrent 354 K USD -79%
Liabilities 6.72 M USD -28%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.28 M USD -194%
Retained Earnings (Accumulated Deficit) -340 M USD -7.88%
Stockholders' Equity Attributable to Parent 33.4 M USD -31.7%
Liabilities and Equity 40.1 M USD -31.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.16 M USD +36.4%
Net Cash Provided by (Used in) Financing Activities 7.86 M USD
Net Cash Provided by (Used in) Investing Activities 15.5 M USD
Common Stock, Shares Authorized 290 M shares 0%
Common Stock, Shares, Issued 49 M shares +5.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.16 M USD -47.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.46 M USD -22.8%
Deferred Tax Assets, Valuation Allowance 83 M USD +8.71%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 83.3 M USD +8.25%
Operating Lease, Liability 1.04 M USD
Payments to Acquire Property, Plant, and Equipment 34 K USD -87.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.7 M USD +40.7%
Lessee, Operating Lease, Liability, to be Paid 1.08 M USD
Property, Plant and Equipment, Gross 4.93 M USD 0%
Operating Lease, Liability, Current 1.04 M USD -17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.39 M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.43 M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 280 K USD -49.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43 M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 59.3 M USD +5.86%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 12.8 M USD +0.81%
Operating Lease, Payments 1.85 M USD +7.67%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 23 K USD -59.6%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.34 M USD -4.13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%